Medistim

Expanding Healthcare Markets Will Offset Elevated Valuation Risks

AnalystConsensusTarget

Not Invested

Consensus Narrative from 2 Analysts

Published

06 Feb 25

Updated

21 Aug 25

AnalystConsensusTarget's Fair Value

NOK 230.00

14.3% overvalued

21 Aug

NOK 263.00

60.4%

15.4%

Author's Valuation

NOK 230.0

14.3% overvalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on13 Mar 25
Fair value Increased 2.22%

AnalystConsensusTarget Fair Value

NOK 230.0

14.3% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

7.30%

Medical Equipment revenue growth rate

0.44%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.80%

Calculation

NOK 0

Earnings '28

29.87x

PE Ratio '28

NOK 0

Market Cap '28

NOK 0

Market Cap '28

18.31m

No. shares '28

NOK 0

Share Price '28

NOK 0 Share Price '28

Discounted to 2025 @ 6.80% p.a.

NOK 0

Fair Value '25

Expanding Healthcare Markets Will Offset Elevated Valuation Risks

Shared on13 Mar 25Fair value Increased 2.22%

Shared on13 Mar 25
Fair value Increased 2.22%